Novartis has reported that a Phase III trial of LBH589 (panobinostat) in combination with bortezomib and dexamethasone met the primary endpoint of significantly extending progression-free survival (PFS) in patients with relapsed or relapsed and refractory multiple myeloma when compared to bortezomib plus dexamethasone alone. Full results from the trial are being evaluated and will be presented at an upcoming medical congress and discussed with regulatory authorities worldwide. LBH589 showed sig...